Efficacy of Cilostazol Administration in Alzheimer’s Disease Patients with White Matter Lesions: A Positron-Emission Tomography Study
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy of Cilostazol Administration in Alzheimer’s Disease Patients with White Matter Lesions: A Positron-Emission Tomography Study
Authors
Keywords
Alzheimer’s disease, cilostazol, positron-emission tomography study
Journal
Neurotherapeutics
Volume -, Issue -, Pages -
Publisher
Springer Nature
Online
2019-02-14
DOI
10.1007/s13311-018-00708-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Supratherapeutic concentrations of cilostazol inhibits β-amyloid oligomerization in vitro
- (2018) Hidenobu Shozawa et al. NEUROSCIENCE LETTERS
- Cilostazol Use Is Associated with Reduced Risk of Dementia: A Nationwide Cohort Study
- (2017) Shu-Yu Tai et al. Neurotherapeutics
- Cilostazol Suppresses Aβ-induced Neurotoxicity in SH-SY5Y Cells through Inhibition of Oxidative Stress and MAPK Signaling Pathway
- (2017) Tatsunori Oguchi et al. Frontiers in Aging Neuroscience
- Glucose deprivation increases tau phosphorylation via P38 mitogen-activated protein kinase
- (2015) Elisabetta Lauretti et al. AGING CELL
- Cilostazol Add-On Therapy in Patients with Mild Dementia Receiving Donepezil: A Retrospective Study
- (2014) Masafumi Ihara et al. PLoS One
- Role of metabotropic glutamate receptor 5 signaling and homer in oxygen glucose deprivation-mediated astrocyte apoptosis
- (2013) Maryse Paquet et al. Molecular Brain
- Effects of cilostazol on cognition and regional cerebral blood flow in patients with Alzheimer's disease and cerebrovascular disease: A pilot study
- (2012) Hirofumi Sakurai et al. Geriatrics & Gerontology International
- The Alzheimer’s Disease Neuroimaging Initiative: A review of papers published since its inception
- (2011) Michael W. Weiner et al. Alzheimers & Dementia
- Protective effect of the phosphodiesterase III inhibitor cilostazol on amyloid β-induced cognitive deficits associated with decreased amyloid β accumulation
- (2011) Sun Haeng Park et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Fluorodeoxyglucose positron emission tomography: emerging roles in the evaluation of putative Alzheimer's disease-modifying treatments
- (2011) Eric M. Reiman NEUROBIOLOGY OF AGING
- Neuroimaging in Dementia
- (2011) Maria Carmela Tartaglia et al. Neurotherapeutics
- Cilostazol prevents amyloid β peptide25-35-induced memory impairment and oxidative stress in mice
- (2010) Masayuki Hiramatsu et al. BRITISH JOURNAL OF PHARMACOLOGY
- CREB's control of intrinsic and synaptic plasticity: implications for CREB-dependent memory models
- (2010) Eva Benito et al. TRENDS IN NEUROSCIENCES
- Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
- (2009) Clifford R Jack et al. LANCET NEUROLOGY
- Protective Effects of Cilostazol against Transient Focal Cerebral ischemia and Chronic Cerebral Hypoperfusion Injury
- (2008) Jeong Hyun Lee et al. CNS Neuroscience & Therapeutics
- Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer’s disease
- (2008) Yi Li et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Cilostazol preserves CA1 hippocampus and enhances generation of immature neuroblasts in dentate gyrus after transient forebrain ischemia in rats
- (2008) Jeong Hyun Lee et al. EXPERIMENTAL NEUROLOGY
- Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease
- (2008) P. Hemachandra Reddy et al. TRENDS IN MOLECULAR MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now